



**PRIVATE & CONFIDENTIAL**

Date: 26 September 2025

Kontafarma China Holdings Limited  
Rooms 12A15–12A20, 12A/F, Sun Hung Kai Centre  
30 Harbour Road  
Wanchai  
Hong Kong

Attention: The Board of Directors

Dear Sirs,

**Re: Kontafarma China Holdings Limited (the “Company”) – Discloseable and Connected Transaction in relation to the Construction Contract for Beijing R&D Complex**


We refer to the circular of the Company dated 26 September 2025 (the “**Circular**”) relating to the Connected Transaction in relation to the Construction Contract for Beijing R&D Complex. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Circular.

We have given and have not withdrawn our written consent to the issue of the Circular with the inclusion of our letter and opinion dated 26 September 2025 and reference to our name, in the form and context in which they respectively included.

As at the Latest Practicable Date, we did not have any shareholding in any member of the Group or any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group.

As at the Latest Practicable Date, we had no direct or indirect interest in any assets which had been acquired or disposed of by or leased to any member of the Group, or were proposed to be acquired or disposed of by or leased to any member of the Group, since 31 December 2024, the date to which the latest published audited consolidated financial statements of the Group were made up.

Yours faithfully,  
For and on behalf of  
**Aurelius Corporate Finance Limited**

A handwritten signature in black ink, appearing to be 'M. Leung', written over a horizontal line.

Matthew Leung  
Managing Director